| Literature DB >> 22646809 |
Eduard Rovira-Vallbona1, Gemma Moncunill, Quique Bassat, Ruth Aguilar, Sonia Machevo, Laura Puyol, Llorenç Quintó, Clara Menéndez, Chetan E Chitnis, Pedro L Alonso, Carlota Dobaño, Alfredo Mayor.
Abstract
BACKGROUND: The factors involved in the progression from Plasmodium falciparum infection to severe malaria (SM) are still incompletely understood. Altered antibody and cellular immunity against P. falciparum might contribute to increase the risk of developing SM.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22646809 PMCID: PMC3464173 DOI: 10.1186/1475-2875-11-181
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Characteristics of the study population
| Age (months) | 28 (16, 39) | 29 (15, 38) | ||
| Males, n (%) | 42 (63) | 42 (63) | ||
| | | | | |
| Temperature (°C) | 38.6 (37.9, 39.2) | 38 (36.4, 39.5) | 0.3 (−0.7, 2.2) | 0.227 |
| Weight (kg) | 11.1 (8.9, 13) | 10.9 (9.6, 12.8) | 0 (−1.6, 1.2) | 1.000 |
| Malnutrition, n (%) | 5 (8) | 2 (3) | 4 (6) | 0.453 |
| Oral candidiasis, n (%) | 1 (1) | 1 (1) | 2 (3) | 1.000 |
| Hepatomegaly, n (%) | 13 (19) | 2 (3) | 13 (19) | 0.005 |
| Splenomegaly, n (%) | 35 (52) | 12 (18) | 35 (52) | <0.001 |
| N° of days with symptoms | 1 (1, 3) | 1 (1, 2) | 0 (0, 1) | 0.192 |
| Parasitaemia by qPCR, (×103/μL) | 34.2 (7.5, 151.3) | 13.3 (1.7, 51.6) | 2.1 (−1.0, 21.8) | 0.087 |
| Parasitaemia by microscopy, (×103/μL) | 40.4 (17.3, 99.3) | 34.7 (11.5, 71.3) | 12.9 (−10.3, 58.3) | 0.036 |
| Multiplicity of infection | 3 (2, 4) | 3 (3, 4) | 0 (−1, 2) | 0.070 |
| Packed cell volume (%) | 26 (16, 31) | 31 (28, 34) | −6 (−15, 0) | <0.001 |
| Platelets (×109/L) | 117 (70, 185) | 145 (92, 192) | −38 (−110, 43) | 0.043 |
| Glucose (mM) | 5.8 (4.6, 7) | 5.8 (5.3, 6.9) | −0.1 (−1.6, 1.2) | 0.702 |
| White blood cells (×109/L) | 10 (6.8, 12.7) | 9.1 (7.2, 11.5) | 0.7 (−2.8, 3.5) | 0.110 |
| Lymphocytes (%) | 35.5 (24.7, 46) | 40.6 (30.2, 50.8) | −7.6 (−19.0, 9.1) | 0.008 |
| Neutrophils (%) | 56.9 (42.9, 67.1) | 53.7 (36.9, 65.3) | 5.8 (−5.1, 10.2) | 0.043 |
| Creatinin (U/L) | 34 (30, 38) | 34 (30, 39) | −1 (−6, 6) | 0.470 |
| Bilirubin (μM) | 24 (14, 37) | 13 (10, 21) | 10 (−1, 23) | <0.001 |
| ALT | 31.5 (19, 39) | 28 (1, 36) | 4 (−11, 15) | 0.376 |
| Lactate (mM) | 3.8 (2.3, 5.1) | 2.3 (1.9, 3.2) | 1.0 (−0.3, 2.4) | 0.001 |
| Prostration, n (%) | 50 (75) | | | |
| ARD | 34 (51) | | | |
| Severe anaemia, n (%) | 22 (33) | | | |
| Multiple seizures, n (%) | 19 (28) | | | |
| Hypoglycaemia, n (%) | 5 (8) | | | |
| Cerebral malaria, n (%) | 3 (5) | | | |
| N° of SM symptoms, n (%): | | | | |
| One | 23 (34) | | | |
| Two | 27 (40) | | | |
| ≥ three | 17 (25) | |||
Presented as medians (inter-quartile range), except when indicated. qPCR, quantitative real-time polymerase chain reaction; ALT, alanine aminotransferase; ARD, acidosis and/or respiratory distress.
Fever, cough or vomits.
Matched comparison reports the median difference (inter-quartile range) between SM and UM values for continuous variables or the number (%) of divergent pairs for categorical variables. P-values calculated using McNemar´s or Sign test for matched pairs. All comparisons were corrected by the Monte Carlo permutation test (1000 random permutations).
Figure 1IgG antibody responses to merozoite antigens (A) and() lysate (B). Seroprevalence is represented by bars as the % of responders; plasma levels are represented by dot plots, with horizontal lines indicating median values. Data from children with SM is shown as shaded bars/dots; data from children with UM is shown as open bars/dots. Results of matched comparisons are reported in the x axis as the number (%) of divergent pairs for IgG seroprevalence, and the median difference (inter-quartile range) of IgG levels between SM and UM. P-values were calculated using McNemar’s or Sign test. All comparisons were corrected by the Monte Carlo permutation test (1000 random permutations). Thresholds for seroprevalence (OD): MSP-119 = 0.560, EBA-175 = 0.628, AMA-1 = 0.578, DBLα = 0.489, P. falciparum lysate = 0.034. Median difference (inter-quartile range) of IgM levels against uninfected erythrocytes lysate between SM and UM = −0.01 [−0.03, 0.01], P = 0.175.
IgG antibody responses to infected erythrocytes surface antigens
| R29 | 64 (96) | 65 (97) | 5 (7) | 1.000 | 11.5 (8.7, 18.2) | 9.9 (6.6, 20.2) | 2.0 (−8.6, 9.1) | 0.088 |
| FCR3CSA | 8 (12) | 11 (16) | 15 (22) | 0.608 | 7.6 (6.6, 9.3) | 7.7 (6.7, 9.2) | −0.3 (−2.3, 1.6) | 0.609 |
| E8BCD36 | 58 (87) | 62 (93) | 14 (21) | 0.414 | 6.7 (4.2, 11.3) | 6.9 (4.5, 10.7) | −0.8 (−4.3, 4.5) | 0.636 |
| ITGICAM1 | 11 (16) | 15 (22) | 24 (36) | 0.300 | 1.1 (0.1, 2.1) | 1.3 (0.2, 2.5) | −0.4 (−2.5, 1.6) | 0.345 |
| MOZ1 | 17 (25) | 18 (27) | 25 (37) | 0.666 | 28.0 (23.6, 31.8) | 26.9 (24.5, 33.9) | 0.01 (−5.5, 4.9) | 1.000 |
| MOZ2 | 40 (60) | 36 (54) | 34 (51) | 0.367 | 1.8 (0.8, 5.9) | 1.6 (0.8, 4.8) | 0.7 (−2.3, 3.8) | 0.334 |
| MOZ3 | 32 (48) | 30 (45) | 34 (51) | 0.611 | 2.6 (1.6, 4.1) | 2.4 (1.3, 4.9) | 0.2 (−2.3, 2.3) | 0.650 |
| MOZ4 | 47 (70) | 44 (66) | 27 (40) | 0.704 | 5.3 (−1.4, 24.9) | 3.3 (−1.4, 13.1) | 2.8 (−11.9, 19.1) | 0.329 |
| MOZ5 | 51 (76) | 56 (83) | 24 (36) | 0.293 | 88.0 (53.1, 115.4) | 83.4 (62.3, 129.9) | −7.4 (−45.7, 35.6) | 0.727 |
| PLC1 | 0 (0) | 3 (4) | 3 (4) | 0.255 | 58.3 (53.2, 64.8) | 60.7 (51.9, 67.5) | −1.1 (−8.7, 7.3) | 0.547 |
| PLC2 | 0 (0) | 3 (4) | 3 (4) | 0.255 | 19.8 (12.3, 24.2) | 18.6 (10.1, 24.5) | −0.7 (−8.2, 8.9) | 0.907 |
MOZ, isolates from Mozambican children; PLC, placental isolates from Mozambican women.
Presented as the number (%) of responders. Matched comparison reports the number (%) of divergent pairs. P-values calculated using McNemar’s test. Thresholds for seroprevalence (MFI): R29 = 5.1, FCR3CSA = 10.1, E8BCD36 = 2.6, ITGICAM = 2.7, MOZ1 = 31.7, MOZ2 = 1.4, MOZ3 = 2.9, MOZ4 = 0.4, MOZ5 = 52.6, PLC1 = 107.6, PLC2 = 42.9.
Presented as medians (inter-quartile range) of MFI values. Matched comparison reports the median difference (inter-quartile range) of IgG levels between SM and UM. P-values calculated using Sign test.
All comparisons were corrected by the Monte Carlo permutation test (1000 random permutations).
Figure 2IgM antibody responses to merozoite antigens (A) and() lysate (B). Seroprevalence is represented by bars as the % of responders; plasma levels are represented by dot plots, with horizontal lines indicating median values. Data from children with SM is shown as shaded bars/dots; data from children with UM is shown as open bars/dots. Results of matched comparisons are reported in the x axis as the number (%) of divergent pairs for IgM seroprevalence, and the median difference (inter-quartile range) of IgM levels between SM and UM. P-values were calculated using McNemar’s or Sign test. All comparisons were corrected by the Monte Carlo permutation test (1000 random permutations). Thresholds for seroprevalence (OD): MSP-119 = 0.605, EBA-175 = 0.514, AMA-1 = 0.554, DBLα = 0.444, P. falciparum lysate = 0.057. Median difference (inter-quartile range) of IgG levels against uninfected erythrocytes lysate between SM and UM = −0.02 [−0.2, 0.1], P = 1.000.
Figure 3Plasma concentrations of cytokines and chemokines.(A) Pro-inflammatory cytokines, (B) immuno-regulatory/anti-inflammatory cytokines, (C) Th1 cytokines, (D) pro-inflammatory chemokine and (E) Th2 cytokine. Percentage of detectable cytokines/chemokines is represented by bars; concentrations are represented by dot plots, with horizontal lines indicating median values. Data from children with SM is shown as shaded bars/dots; data from children with UM is shown as open bars/dots. Results of matched comparisons are reported in the x axis as the number (%) of divergent pairs for cytokine/chemokine prevalence, and the median difference (inter-quartile range) of cytokine/chemokine concentrations between SM and UM (in ng/mL for TGF-β1). P-values were calculated using McNemar’s or Sign test. All comparisons were corrected by the Monte Carlo permutation test (1000 random permutations).